Sugi Predict

Sugi Predict / Compounds / SCHEMBL1661739

SCHEMBL1661739

SCHEMBL1661739

CCOC(=O)CC1CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.51
▸ NAMPT P43490 1/20 0.43
▸ USP2 O75604 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ GPR119 Q8TDV5 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ ADORA1 P30542 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HPGD P15428 2/20 0.37
▸ RECQL P46063 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ GLA P06280 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ TSHR P16473 1/20 0.36
▸ GLS O94925 1/20 0.35
▸ EPHX1 P07099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25920440 0.88 NR1H2 (0.65) NR1H2NAMPTUSP2SMN1; SMN2GPR119
SCHEMBL15874584 0.88 NR1H2 (0.43) NR1H2GPR119ALDH1A1MEN1KMT2A
SCHEMBL21063433 0.88 NR1H2 (0.47) NR1H2NAMPTUSP2SMN1; SMN2GPR119
SCHEMBL21557908 0.88 NR1H2 (0.65) NR1H2NAMPTUSP2SMN1; SMN2GPR119
SCHEMBL1899485 0.88 NR1H2 (0.43) NR1H2GPR119ALDH1A1MEN1KMT2A
SCHEMBL6404713 0.86 GLS (0.50) NR1H2ALDH1A1MEN1KMT2AMAPT
SCHEMBL792648 0.86 GLS (0.50) NR1H2ALDH1A1MEN1KMT2AMAPT
SCHEMBL771790 0.86 GLS (0.50) NR1H2ALDH1A1MEN1KMT2AMAPT
SCHEMBL30793810 0.85 GLS (0.47) NR1H2ALDH1A1MEN1KMT2AMAPT
SCHEMBL21063461 0.85 NR1H2 (0.49) NR1H2NAMPTUSP2SMN1; SMN2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4634194-A1 SUBSTITUTED DIHYDROPYRROLO [3, 4-D] PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2025-10-22 — — EP disclosed
WO-2025134078-A1 ORGANIC COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMS) SUVEN LIFE SCIENCES LIMITED (IN) 2025-06-26 — — WO disclosed
WO-2025122809-A1 M4 POSITIVE ALLOSTERIC MODULATORS ACADIA PHARMACEUTICALS INC. (US) 2025-06-12 — — WO disclosed
CN-119677513-A Methods and compounds for modulating genetic disease 设计治疗公司 2025-03-21 — — CN disclosed
WO-2024130066-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2024-06-20 — — WO disclosed
WO-2024130066-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2024-06-20 — — WO disclosed
WO-2024130068-A1 SUBSTITUTED DIHYDROPYRROLO [3, 4-D] PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2024-06-20 — — WO disclosed
US-20240190869-A1 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES PFIZER (US) 2024-06-13 — — US disclosed
US-11905284-B2 5,7-dihydro-pyrrolo-pyridine derivatives PFIZER INC. (US) 2024-02-20 — — US disclosed
US-20230192690-A1 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES PFIZER (US) 2023-06-22 — — US disclosed
US-7842685-B2 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-11-30 — — US disclosed
US-20100029611-A1 S1P1 receptor agonists and use thereof AMGEN INC. (US) 2010-02-04 — — US disclosed
WO-2009154780-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC. (US) 2009-12-23 — — WO disclosed
WO-2009154775-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC. (US) 2009-12-23 — — WO disclosed
US-5648368-A ANTICOAGULANTS MERCK & CO., INC. (US) 1997-07-15 — — US disclosed
EP-0673247-A4 FIBRINOGEN RECEPTOR ANTAGONISTS. MERCK & CO INC (US) 1996-05-01 — — EP disclosed
US-5455243-A Anticoagulants MERCK & CO., INC. (US) 1995-10-03 — — US disclosed
EP-0673247-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 1995-09-27 — — EP disclosed
WO-1994012181-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1994-06-09 — — WO disclosed
US-5281585-A Secondary amide containing antagonist MERCK & CO., INC. (US) 1994-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190869-A1 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES CHRM1, CHRM5, CHRM2 NR1H2 391/4885NAMPT 1268/4885USP2 4745/4885
US-20100029611-A1 S1P1 receptor agonists and use thereof S1PR1, S1PR5, S1PR2 NR1H2 51/4885NAMPT 2475/4885USP2 4518/4885
US-20230192690-A1 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES CHRM1, CHRM5, CHRM2 NR1H2 391/4885NAMPT 1268/4885USP2 4745/4885
US-11905284-B2 5,7-dihydro-pyrrolo-pyridine derivatives CHRM1, CHRM5, CHRM2 NR1H2 391/4885NAMPT 1268/4885USP2 4745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.